Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
Cerecin
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, global function, activities of daily living, resource utilisation, safety, and tolerability, in participants with mild to moderate AD dementia. This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre design in up to 535 participants.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- ALTER-AD
- status
- NOT_YET_RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 535
- sponsor
- Cerecin
- conditions
- Alzheimer Disease
- interventions
- DRUG: Tricaprilin; DRUG: Placebo
- start date
- 2026-12-01
- start date type
- ESTIMATED
- primary completion date
- 2029-06-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT05809908
- Published
- Apr 12, 2023
- Updated
- Jul 1, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT05809908
- Categories
- Alzheimer Disease
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials